Working… Menu

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer (REPROVe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03281681
Recruitment Status : Withdrawn (Alternate study design for ovarian cancer under discussion)
First Posted : September 13, 2017
Last Update Posted : October 18, 2019
Information provided by (Responsible Party):
DelMar Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : September 2022